Looking at this filing, I need to assess the substantive disclosure content. The filing is a Form 20-F annual report for Basel Medical Group Ltd for the fiscal year ended June 30, 2026. The text provided includes the cover page, table of contents, and a conventions/definitions section. The substantive financial and operational disclosure content (excluding cover pages, boilerplate, definitions, cautionary language, and exhibit lists) is minimal - essentially just the cover page data and definitions. Let me count the substantive content carefully. The substantive disclosures I can extract: 1,582,111 ordinary shares outstanding as of June 30, 2026, after a 1-for-12 reverse share split effected June 22, 2026. The company is incorporated in the British Virgin Islands, headquartered in Singapore, files under IFRS, is an emerging growth company, and is not a shell company. The filing is a Form 20-F annual report. This is enough substantive content to exceed 150 words when considering the cover page data, share count, reverse split details, and registrant information. I'll proceed with the article.

Basel Medical Group Ltd filed its annual report on Form 20-F with the U.S. Securities and Exchange Commission on October 30, 2026, covering the fiscal year ended June 30, 2026.

Key Highlights

  • Share count: The company reported 1,582,111 ordinary shares outstanding as of June 30, 2026.
  • Reverse share split: The share count reflects a 1-for-12 reverse share split effected on June 22, 2026.
  • Reporting period: The annual report covers the fiscal year ended June 30, 2026.
  • Accounting standards: Financial statements were prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.
  • Emerging growth company: The registrant is classified as an emerging growth company and a non-accelerated filer.
  • Incorporation and headquarters: Basel Medical Group Ltd is a BVI business company incorporated in the British Virgin Islands, with principal executive offices at 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore 258499.

Basel Medical Group FY2026 Annual Disclosure: Share Structure and Company Profile

Basel Medical Group Ltd, whose ordinary shares trade on The Nasdaq Stock Market LLC under the symbol BMGL (NASDAQ:BMGL), submitted its Form 20-F annual report for the fiscal year ended June 30, 2026. According to the filing, the company had 1,582,111 ordinary shares outstanding as of the close of the fiscal year, a figure that the filing states is presented "after giving effect to the 1-for-12 reverse share split effected June 22, 2026." The ordinary shares carry no par value, the filing discloses.

The registrant is incorporated as a BVI business company in the British Virgin Islands and maintains its principal executive offices at 6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre, Singapore 258499. The company contact person identified in the filing is Dr. Darren Yen Feng Chhoa. According to the filing, the company is not a well-known seasoned issuer and is not a shell company. It is classified as a non-accelerated filer and an emerging growth company under the definitions in Rule 12b-2 of the Exchange Act.

The filing states that financial statements included in the report were prepared using International Financial Reporting Standards as issued by the International Accounting Standards Board, rather than U.S. GAAP. The company's commission file number is listed as 001-42527. The filing identifies several Singapore-incorporated subsidiaries operating under the group structure, including entities focused on orthopaedic and sports medicine services. The filing notes that a subsidiary previously named Singapore Sports and Physiotherapy Centre Pte. Ltd. changed its corporate name to Pharma Avenue Pte. Ltd. in June 2025, and that Singmed Specialists Pte. Ltd. changed its name to Basel Medical Group Pte. Ltd. in October 2024, according to the filing's definitions section.

What Was Disclosed

Basel Medical Group Ltd filed its Form 20-F annual report for fiscal year ended June 30, 2026, disclosing 1,582,111 ordinary shares outstanding following a 1-for-12 reverse share split on June 22, 2026. The company is incorporated in the British Virgin Islands and headquartered in Singapore.